Who are mini CYVE, without 3 maintenance courses's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Treatment Choice (TC), CHS-1420, SCTB14, TAK-667, KI1106 4g, QD, TBI-1301.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mini-cyve-without-3-maintenance-courses.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

mini CYVE, without 3 maintenance courses — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mini CYVE, without 3 maintenance courses (mini CYVE, without 3 maintenance courses) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα inhibitor. Area: Oncology.

phase 3 CD47/SIRPα inhibitor CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

mini CYVE, without 3 maintenance courses (mini CYVE, without 3 maintenance courses) — Gustave Roussy, Cancer Campus, Grand Paris. mini CYVE targets the CD47/SIRPα axis to promote phagocytosis of cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mini CYVE, without 3 maintenance courses TARGET	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
TAK-667	TAK-667	Takeda	phase 3	CD47 antibody	CD47
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
TBI-1301	TBI-1301	Takara Bio Inc.	phase 3	CD47 antibody	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα inhibitor class)

BicycleTx Limited · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Kuhnil Pharmaceutical Co., Ltd. · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pharmicell Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mini CYVE, without 3 maintenance courses — Competitive Intelligence Brief. https://druglandscape.com/ci/mini-cyve-without-3-maintenance-courses. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing